Comorbidity and Health Care Resource Use among Commercially Insured Non-Elderly Patients with Diabetic Macular Edema

Ophthalmic Surgery Lasers and Imaging Retina

Volumn 46, Issue 7, 2015, Pages 744-751

  Wallick, Christopher J ^a,b   Hansen, Ryan N ^b   Campbell, Joanna ^a   Kiss, Szilárd ^c   Kowalski, Jonathan W ^a   Sullivan, Sean D ^b  

^a Global Health Outcomes Strategy and Research   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; COHORT ANALYSIS; COMORBIDITY; CONTROLLED STUDY; DIABETIC MACULAR EDEMA; DIABETIC PATIENT; FEMALE; HEALTH CARE PERSONNEL; HEALTH CARE UTILIZATION; HEALTH INSURANCE; HUMAN; MAJOR CLINICAL STUDY; MALE; OPTICAL COHERENCE TOMOGRAPHY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; ADOLESCENT; AMPUTATION; CARDIOVASCULAR DISEASES; COST OF ILLNESS; DIABETES MELLITUS; DIABETIC RETINOPATHY; ECONOMICS; FACTUAL DATABASE; HEALTH CARE PLANNING; INSURANCE; KIDNEY DISEASES; LOWER LIMB; MACULAR EDEMA; MIDDLE AGED; STATISTICS AND NUMERICAL DATA; SURGERY; UTILIZATION;

ADOLESCENT; ADULT; AMPUTATION; CARDIOVASCULAR DISEASES; COMORBIDITY; COST OF ILLNESS; DATABASES, FACTUAL; DIABETES MELLITUS; DIABETIC RETINOPATHY; FEMALE; HEALTH RESOURCES; HUMANS; INSURANCE CLAIM REVIEW; KIDNEY DISEASES; LOWER EXTREMITY; MACULAR EDEMA; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES;

EID: 84939454112     PISSN: 23258160     EISSN: 23258179     Source Type: Journal    
DOI: 10.3928/23258160-20150730-09     Document Type: Article

References (26)

1. Bhagat N, Grigorian RA, Tutela A, Zarbin MA. Diabetic macular edema: pathogenesis and treatment. Surv Ophthalmol. 2009;54(1):1-32.
2. Centers for Disease Control and Prevention. National diabetes fact sheet: national estimates and general information on diabetes and pre-diabetes in the United States, 2011. 2011. Available at: www.cdc.gov/diabetes/pubs/pdf/ndfs-2011.pdf. Accessed July 15, 2015.
3. American Academy of Ophthalmology. Preferred Practice Pattern. Diabetic Retinopathy. 2008. Available at: www.one.aao.org/assets/99d84214-4366-4acd-97ad/diabetic-retinopathy-pdf. Accessed July 15, 2014.
4. Chen E, Looman M, Laouri M, et al. Burden of illness of diabetic macular edema: literature review. Curr Med Res Opin. 2010; 26(7):1587-1597.
5. Zhang W, Liu H, Al-Shabrawey M, Caldwell RW, Caldwell RB. In-fammation and diabetic retinal microvascular complications. J Car-diovasc Dis Res. 2011;2:96-103.
6. Williams R, Airey M, Baxter H, Forrester J, Kennedy-Martin T, Gi-rach A. Epidemiology of diabetic retinopathy and macular oedema: a systematic review. Eye (Lond). 2004;18(10):963-983.
7. Bressler NM, Varma R, Doan Q, et al. Prevalence of Visual Impairment from Diabetic Macular Edema and Relationship to Eye Care from the 2005-2008 National Health and Nutrition Examination Survey (NHANES). Paper presented at: 45th Annual of the Retina Society; October 5, 2012; Washington, DC.
8. Nguyen-Khoa BA, Goehring EL, Werther W, et al. Hospitalized cardiovascular events in patients with diabetic macular edema. BMC Ophthalmol. 2012;12:11.
9. Ramsey S, Summers KH, Leong SA, Birnbaum HG, Kemner JE, Greenberg P. Productivity and medical costs of diabetes in a large employer population. Diabetes Care. 2002;25(1):23-29.
10. Kulkarni AD, Ip MS. Diabetic macular edema: therapeutic options. Diabetes Ther. 2012;3(1):1-14
11. Witkin AJ, Brown GC. Update on nonsurgical therapy for diabetic macular edema. Curr Opin Ophthalmol. 2011;22(3):185-189.
12. Grover D, Li TJ, Chong CC. Intravitreal steroids for macular edema in diabetes. Cochrane Database Syst Rev. 2008;CD005656.
13. O'Doherty M, Dooley I, Hickey-Dwyer M. Interventions for diabetic macular oedema: a systematic review of the literature. Br J Ophthal-mol. 2008;92(12):1581-1590.
14. Shea AM, Curtis LH, Hammill BG, et al. Resource use and costs associated with diabetic macular edema in elderly persons. Arch Oph-thalmol. 2008;126(12):1748-1754.
15. Gonder JR, Walker VM, Barbeau M, et al. Costs and Quality of Life in Diabetic Macular Edema: Canadian Burden of Diabetic Macular Edema Observational Study (C-REALITY). J Ophthalmol. 2014;2014:939315.
16. Petrella RJ, Blouin J, Davies B, Barbeau M. Prevalence, Demographics, and Treatment Characteristics of Visual Impairment due to Diabetic Macular Edema in a Representative Canadian Cohort. J Oph-thalmol. 2012;2012:159167.
17. Bearelly S, Mruthyunjaya P, Tzeng J P, et al. Identifcation of patients with diabetic macular edema from claims data: a validation study. Arch Ophthalmol. 2008;126(7):986-989.
18. Danielson, E. White paper: Health research data for the real world: the MarketScan databases. Truven Health Analytics; 2014. Jan.
19. Sharma S, Johnson D, Abouammoh M, Hollands S, Brissette A. Rate of serious adverse effects in a series of bevacizumab and ranibizumab injections. Can J Ophthalmol. 2012;47(3):275-279.
20. Carneiro AM, Barthelmes D, Falcao MS, et al. Arterial thromboem-bolic events in patients with exudative age-related macular degeneration treated with intravitreal bevacizumab or ranibizumab. Ophthal-mologica. 2011;225(4):211-221.
21. Winnik S, Lohmann C, Siciliani G, et al. Systemic VEGF inhibition accelerates experimental atherosclerosis and disrupts endothe-lial homeostasis-implications for cardiovascular safety. Int J Cardiol. 2013;168(3):2453-2461.
22. Buchmueller TC, Allen ME, Wright W. Assessing the validity of insurance coverage data in hospital discharge records: California OSHPD data. Health Serv Res. 2003;38(5):1359-1372.
23. Kiss S, Liu Y, Brown J, et al. Clinical utilization of anti-vascular endo-thelial growth-factor agents and patient monitoring in retinal vein occlusion and diabetic macular edema. Clin Ophthalmol. 2014;8:1611-1621.
24. Javey G, Schwartz SG, Flynn HW, Jr. Emerging pharmacotherapies for diabetic macular edema. Exp Diabetes Res. 2012;2012:548732.
25. Kiss S, Liu Y, Brown J, et al. Clinical monitoring of patients with age-related macular degeneration treated with intravitreal bevacizumab or ranibizumab. Ophthalmic Surg Lasers Imaging Retina. 2014;45(4):285-291.
26. Holekamp NM, Liy Y, Yeh WS, et al. Clinical utilization of anti-VEGF agents and disease monitoring in neovascular age-related mac-ular degeneration. Am J Ophthalmol. 2014 157(4):825-833.